Ameriprise
ORGO icon

Ameriprise’s Organogenesis Holdings ORGO Stock Holding History

Ameriprise’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Buy
98,537
+62,626
+174% +$153K ﹤0.01% 3910
2026
Q1 		$85.1K Sell
35,911
-419
-1% -$1.45K ﹤0.01% 3971
2025
Q4 		$188K Buy
36,330
+479
+1% +$2.32K ﹤0.01% 3937
2025
Q3 		$151K Hold
35,851
– – ﹤0.01% 3933
2025
Q2 		$131K Sell
35,851
-35,187
-50% -$131K ﹤0.01% 3860
2025
Q1 		$307K Sell
71,038
-57
-0.1% -$230 ﹤0.01% 3670
2024
Q4 		$228K Sell
71,095
-61,072
-46% -$205K ﹤0.01% 3823
2024
Q3 		$378K Sell
132,167
-300
-0.2% -$841 ﹤0.01% 3579
2024
Q2 		$371K Sell
132,467
-223,984
-63% -$601K ﹤0.01% 3525
2024
Q1 		$1.01M Buy
356,451
+13,976
+4% +$47.5K ﹤0.01% 3161
2023
Q4 		$1.4M Buy
342,475
+9,707
+3% +$27.2K ﹤0.01% 3050
2023
Q3 		$1.06M Sell
332,768
-89,539
-21% -$285K ﹤0.01% 3115
2023
Q2 		$1.4M Sell
422,307
-65,452
-13% -$193K ﹤0.01% 3034
2023
Q1 		$1.04M Sell
487,759
-35,871
-7% -$88.6K ﹤0.01% 3137
2022
Q4 		$1.41M Sell
523,630
-11,023
-2% -$32.2K ﹤0.01% 2967
2022
Q3 		$1.73M Buy
534,653
+80,639
+18% +$364K ﹤0.01% 2845
2022
Q2 		$2.22M Sell
454,014
-4,288
-0.9% -$26.4K ﹤0.01% 2768
2022
Q1 		$3.49M Buy
458,302
+63,111
+16% +$488K ﹤0.01% 2649
2021
Q4 		$3.65M Buy
395,191
+115,899
+41% +$1.23M ﹤0.01% 2677
2021
Q3 		$3.98M Buy
279,292
+62,502
+29% +$971K ﹤0.01% 2543
2021
Q2 		$3.6M Buy
+216,790
New +$4.04M ﹤0.01% 2664

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Ameriprise's ORGO Position: Q2 2026 in Review

Ameriprise increased its Organogenesis Holdings (ORGO) stake by 174% in Q2 2026, buying an estimated $153K and bringing the position to 98,537 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #3910.

Ameriprise first reported a position in ORGO in Q2 2021 and has held it in 21 quarters since. The position peaked at $3.98M in Q3 2021. 136 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

  • Ameriprise held 98,537 shares of Organogenesis Holdings worth $239K as of Q2 2026.
  • Ameriprise bought 62,626 Organogenesis Holdings shares in Q2 2026, an estimated $153K.
  • Organogenesis Holdings made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3910 holding.
  • Ameriprise first reported a position in Organogenesis Holdings in Q2 2021 and has held it in 21 quarters since.
  • Ameriprise's Organogenesis Holdings position peaked at $3.98M in Q3 2021.
  • 136 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.